Definition of a Cytotoxic T Lymphocyte Epitope of the Sin Nombre Hantavirus G2 Glycoprotein by Vollaro, Cindy M.
Worcester Polytechnic Institute
Digital WPI
Masters Theses (All Theses, All Years) Electronic Theses and Dissertations
1999-10-13
Definition of a Cytotoxic T Lymphocyte Epitope
of the Sin Nombre Hantavirus G2 Glycoprotein
Cindy M. Vollaro
Worcester Polytechnic Institute
Follow this and additional works at: https://digitalcommons.wpi.edu/etd-theses
This thesis is brought to you for free and open access by Digital WPI. It has been accepted for inclusion in Masters Theses (All Theses, All Years) by an
authorized administrator of Digital WPI. For more information, please contact wpi-etd@wpi.edu.
Repository Citation
Vollaro, Cindy M., "Definition of a Cytotoxic T Lymphocyte Epitope of the Sin Nombre Hantavirus G2 Glycoprotein" (1999). Masters Theses
(All Theses, All Years). 1063.
https://digitalcommons.wpi.edu/etd-theses/1063
DEFINITION OF A CYTOTOXIC LYMPHOCYTE
EPITOPE OF THE SIN NOMBRE HANTAVIRUS G2
GLYCOPROTEIN
by
Cindy M. Vollaro
A Thesis
Submitted to the Faculty
of the
WORCESTER POLYTECHNIC INSTITUTE
In Partial Fulfillment of the Requirement for the
Degree of Master of Science
in
Biology
May 5, 1999
Approved by:
Dr. Jill Rulfs, Major Advisor
Dr. Francis A. Ennis, Thesis Committee
Dr. Alan L. Rothman, Thesis Committee
Dr. Ronald D. Cheetham, Department Head
iAbstract
Sin Nombre virus is a hantavirus first recognized in New Mexico in 1993. This
virus is responsible for causing Hantavirus Pulmonary Syndrome, an acute, life
threatening illness characterized by pulmonary edema, capillary leaking, and extreme
respiratory distress.  CD8+ cytotoxic T-cell lines specific for Sin Nombre virus were
isolated from the peripheral blood mononuclear cells (PBMC) of a donor (NM3) who
was naturally infected with the Sin Nombre virus, and has survived hantavirus pulmonary
syndrome (HPS).  Cytotoxic T lymphocyte (CTL) assays showed that one of these cell
lines, 10K, specifically recognizes a nine amino acid epitope, TAHGVGIIP (amino acids
664-672 of the precursor GPC protein), which is located in the G2 protein after cleavage.
Another cell line, 10c27, specifically recognized an eight amino acid epitope,
AHGVGIIP (amino acids 665-672 of the precursor GPC protein), located in the G2
protein after cleavage.  Using polymerase chain reaction (PCR) and CTL assays, the
recognition of these epitopes was shown to be restricted by the B35.01 Class 1 human
leukocyte associated antigen (HLA) allele.  This information will be useful in creating a
vaccine for use in immunizing people against the Sin Nombre hantavirus, as well as
elucidating the pathogenesis of this disease.
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1Introduction
Hantaviruses
Hantaviruses, which are members of the family Bunyaviridae, are enveloped
negative-sense single stranded RNA viruses whose genome is divided into three genome
segments termed, S, M, and L, representing Small, Medium and Large, respectively (Hart
and Bennett, 1994).    The small segment (approximately 2000 nucleotides) codes for the
nucleocapsid protein, N, the medium segment (approximately 3700 nucleotides) codes
for the two envelope glycoproteins, G1 and G2, and the large segment (approximately
6500 nucleotides) codes for the viral transcriptase, L.  The general structure and genome
segments of a hantavirus are shown in Figure 1  (Hjelle et al., 1995).
Figure 1.  General structure of Hantavirus Showing Genome and Basic Virion Structure
and Coding Assignments  (Hjelle et al., 1995)
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Hantaviruses spread through direct contact with or inhalation of aerosolized
rodent excreta or secretions, such as feces, urine and saliva (Zaki et al., 1995).  These
viruses constitute the only genus in the bunyaviridae family that is not transmitted by an
insect vector (Hart and Bennett, 1994).  The rodents that carry hantaviruses are
persistently infected with the virus and do not show any signs of disease (Hart and
Bennett, 1994).
Hantaviruses cause two distinct types of disease in humans:  hemorrhagic fever
with renal syndrome (HFRS) and hantavirus pulmonary syndrome (HPS).
Hemorrhagic Fever with Renal Syndrome (HFRS)
The hantaviruses that cause HFRS include Hantaan virus, which is the prototype
hantavirus, Seoul virus, and Dobrava virus.  The rodent hosts for the hantaviruses which
cause HFRS are usually indigenous to the Old World (Hjelle, 1995).
The main signs of HFRS are hematologic abnormalities, prominent (often severe)
renal involvement and increased vascular permeability (Duchin et al., 1994).  There are
five distinct phases of HFRS:  febrile, hypotensive, oliguric, diruetic, and convalescent
(Butler and Peters, 1994).  Approximately thirty to forty percent of infected patients have
only a minimal illness, and only twenty to thirty percent of patients have a moderate or
severe illness (Duchin et al., 1994).
Hantavirus Pulmonary Syndrome (HPS)
Hantavirus Pulmonary syndrome was first recognized in 1993.  This disease is
caused by hantaviruses carried by rodent hosts that are indigenous to the New World
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(Hjelle, 1995).  Two strains of hantaviruses that cause HPS are the Sin Nombre virus
and the Black Creek Canal virus (Morzunov et al., 1998).
This disease is characterized by extreme respiratory distress, including pulmonary
edema and capillary leaking in the lung (Ennis et al., 1997).  This disease passes through
three phases:  prodromal, cardiopulmonary, and convalescent (Butler and Peters, 1994).
In the U.S., as of April 7, 1999, 211 cases of HPS have been identified spread across 30
states.  Two of these cases occurred in 1999, and of the reported cases the overall
mortality rate is 43%, or 90 deaths (Young, 1999).
Sin Nombre Virus
Sin Nombre virus, shown in Figure 2, was the first isolated hantavirus shown to
cause HPS.  This virus was discovered in New Mexico in May of 1993, and was
originally termed the Muerto Canyon Virus and the Four Corners Virus.  The rodent
vector of Sin Nombre virus is Peromyscus maniculatus, commonly known as the deer
mouse (Chapman and Khabbaz, 1994).
Figure 2.  Electron Micrograph of Sin Nombre Virus  (Hjelle, 1995)
4The structure of Sin Nombre virus is consistent with the structure of other
hantaviruses.  The S segment of the genome is 2059 nucleotides in length and codes for
the nucleocapsid protein, which is 428 amino acids long.  The M genome segment is
3696 nucleotides in length and codes for the GPC precursor protein which is cleaved into
the G1 protein (652 amino acids) and the G2 protein (488 amino acids) after translation
(Spiropoulou et al., 1994) (Figure 3).  The L segment of the genome is 6,562 nucleotides
coding for  a putative 2,153 amino acid long L polymerase (Chizhikov et al., 1995).
Figure 3.  Amino Acid Sequence of Sin Nombre Precursor G1 and G2 Protein, Genebank
Accession Number AAA75530 (Spiropoulou et al., 1994). Boldface indicates G2 protein.
Highlighted area indicates protein expressed by recombinant vac/G2Afl2 virus.
   1 mvgwvciflv vlttataglt rnlyelkiec phtvglgqgy vtgsveitpi lltqvadlki
  61 esscnfdlhv patttqkynq vdwtkksstt estnagattf eaktkeinlk gtcnippttf
 121 eaayksrktv icydlacnqt hclptvhlia pvqtcmsvrs cmigllssri qviyektycv
 181 tgqlieglcf ipthtialtq pghtydtmtl pvtcflvakk lgtqlklave leklitgvsc
 241 tensfqgyyi cfigkhsepl fvptmedyrs aelftrmvln prgedhdpdq ngqglmriag
 301 pvtakvpste ttetmqgiaf agapmyssfs tlvrkadpey vfspgiiaes nhsvcdkktv
 361 pltwtgflav sgeiekitgc tvfctlagpg asceaysetg ifnissptcl vnkvqkfrgs
 421 eqrinfmcqr vdqdvvvycn gqkkviltkt lvigqciytf tslfslipgv ahslavelcv
 481 pglhgwatta llitfcfgwl lipavtliil kilrlltfsc shysteskfk vilervkvey
 541 qktmgsmvcd ichhecetak elethkkscp egqcpycmti testesalqa hfaickltnr
 601 fqenlkkslk rpevrkgcyr tlgvfryksr cyvglvwgil ltteliiwaa sadtplmesg
 661 wsdtahgvgi ipmktdleld falassssys yrrklvnpan qeetlpfhfq ldkqvvhaei
 721 qnlghwmdgt fniktafhcy geckkyaypw qtakcffekd yqyetswgcn ppdcpgvgtg
 781 ctacgvyldk lrsvgkayki vslkytrkvc iqlgteqtck hidvndclvt psvkvcmigt
 841 isklqpgdtl lflgpleqgg iilkqwctts cvfgdpgdim sttsgmrcpe htgsfrkicg
 901 fattptceyq gntvsgfqrm matrdsfqsf nvtephitsn rlewidpdss ikdhinmvln
 961 rdvsfqdlsd npckvdlhtq sidgawgsgv gftlvctvgl tecanfitsi kacdsamcyg
1021 atvtnllrgs ntvkvvgkgg hsgslfkcch dtdcteegla aspphldrvt gynqidsdkv
1081 yddgappcti kcwftksgew llgilngnwv vvavlivili lsillfsffc pvrsrknkan
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Cytotoxic T Lymphocytes
Cytotoxic T lymphocytes are T cells which recognize antigens presented on an
infected cell and lyse the infected cell.  These cytotoxic cells are usually CD8+, however,
there are some which have been shown to be CD4+.  Cytotoxic T lymphocytes have been
shown to play a major role in recovery from viral infections.  Some cytotoxic T
lymphocytes can produce cytokines which can help to modify the immune response by
stimulating other immune cells (Coleman, Lombard and Sicard, 1992).
Pathogenesis of HPS
Current research on the pathogenesis of HPS suggests that elevated levels of
cytokine production in the lungs contribute to the respiratory distress and pulmonary
edema associated with HPS (Mori et al., 1999).  These cytokine-producing cells have
been shown to be localized specifically in the lungs of patients who have died from HPS.
It is believed, but still needs to be determined, that the cytokine producing cells, which
may cause the capillary-leak syndrome, include activated T lymphocytes that have
infiltrated the lungs. Elevated levels of cytokine producing cells were not observed in
patients who did not have acute lung disease (Mori et al., 1999).
The Major Histocompatibility Complex
The major histocompatibility complex (MHC) is the set of genes that determine
what a cell recognizes as “self” and “non-self”.  This complex presents the antigenic
peptide or epitope which is recognized by the T cell receptor on lymphocytes.  In
humans, this gene complex is referred to as the human leukocyte-associated (HLA)
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complex (Coleman, Lombard and Sicard, 1992).  These genes, located on chromosome
6, encode the three classes of HLA antigens designated Class I, II and III.  These genes
are highly polymorphic, resulting in many different alleles for each of the classes and,
therefore, many different HLA molecules.  Each class of HLA antigens has a different
role in the immune response.
Class I Antigens
There are three HLA Class I genes designated HLA-A, HLA-B, and HLA-C.
Each of the different alleles of these genes are distinguished by numbering the distinct
alleles, such as HLA-A2, HLA-B35 or HLA-B7.  In some cases, very similar alleles are
subtyped, such as HLA-B35.01 and HLA-B35.02 (which differ by only a few
nucleotides).
Each of the HLA genes codes for a peptide binding protein that is expressed on
the surface of the cell.  Since each person carries two alleles for each class I antigen,
there is a wide variety of Class I HLAs which can be expressed on the cell surface.
 Class I HLA Restriction of an Epitope
The peptide binding region of class I antigens restrict the foreign peptide antigens
that will be presented for recognition to CD8+ cytotoxic T-lymphocytes. For a specific
antigenic determinant, or epitope, to be recognized by a cytotoxic T cell, the larger
antigen, such as a virus, must be processed by an infected cell, and presented as small
peptides on the cell surface by the appropriate Class I molecule (Figure 4). CD8+
cytotoxic T lymphocytes will only recognize an epitope, usually nine amino acids in
7
length, in the context of a specific class I molecule, a phenomenon called HLA
restriction (such as an HLA-A7 restricted epitope).
Figure 4.  Recognition of Antigen By Human Cytotoxic CD8+ Cells.  Foreign Antigen is
recognized by CD8+ cytotoxic T cells only when it is associated with “self” class I HLA
molecules.  Binding of the complex to the T cell receptor is apparently enhanced by
accessory association of other self class I molecules with CD8 molecules adjacent to the
T cell receptor (Coleman, Lombard and Sicard, 1992).
Usually, the HLA Class I molecule’s motif, or format for a recognizable epitope,
consists of two anchoring amino acids, which are usually conserved, and other non-
anchor residues, which can be more diverse (Reammensee Friede and Stevanovic, 1995).
When defining an epitope, it is extremely important to realize that this epitope can only
be recognized by CD8+ cytotoxic T lymphocytes in the context of the appropriate HLA
antigen.
Previous Studies on Human Hantavirus-Specific T Lymphocytes
Research on cytotoxic T lymphocyte cell lines specific for the Sin Nombre virus
has identified an HLA-C7 restricted epitope, ERIDDFLAA (amino acids 234-242), on
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the nucleocapsid protein as well as a HLA-B35 restricted epitope, LPIILKALY (amino
acids 131-139), also on the nucleocapsid protein.  Both of these epitopes were recognized
by CD8+ T cell lines.  Another epitope, GIQLDQKII (amino acids 372-380), on the
nucleocapsid protein, was recognized by a CD4+ T cell line (Ennis et al., 1997).
Epitopes for Hantaan virus have also been defined.  One CD8+ T cell line was
specific for  a HLA-B51 restricted epitope on amino acids 12-20 of the nucleocapsid
protein.  Another CD8+ T cell line was specific for an HLA-A1 restricted epitope on
amino acids 421-429 of the nucleocapsid protein.  Also a CD4+ T cell line has been
shown to be specific for the G1 protein (VanEpps, Schmaljohn and Ennis., 1999).
Goals of Thesis
The goal of this project was to define and characterize the epitope of previously
created CD8+ T lymphocyte lines specific for the Sin Nombre virus.  The cell lines,
isolated from donor NM3, who was infected with the Sin Nombre virus naturally, and
had survived HPS, had been selected for G2 specificity, but the specific epitope causing
the cytotoxic response was still unknown.  The work presented here verified the G2
specificity of several clones by use of recombinant vaccinia virus constructs, and
identified the minimum epitope recognized by two cell lines using peptide-based CTL
assays.  The human leukocyte-associated antigen (HLA) restriction of the epitope was
also determined by use of PCR and CTL assays.
9Methods
Sin Nombre Virus Specific T Cell Lines
Cell lines used were previously isolated as described (Ennis et. al., 1997).
Briefly, a bulk culture was established from the peripheral blood mononuclear cells
(PBMC) of a patient (NM3) previously diagnosed with HPS.  This bulk culture was
stimulated with anti-CD3 monoclonal antibody (12F6 at 0.1µg/ml) and gamma-irradiated
allogeneic PBMC feeders, and screened against autologous Epstein Barr Virus
transformed B-lymphoblastoid cell lines (BLCLs) infected with recombinant vaccinia
constructs which expressed various Sin Nombre viral proteins.  This screen indicated T
cell specificity for the Sin Nombre G2 protein (Scott, unpublished data).
The bulk culture was cloned by limiting dilution.  Resulting cell lines were
determined to be CD8+ by flow cytometric analysis and screened against the target cells
infected with a G2 vaccinia construct and/or a vaccinia construct expressing the first half
of the G2 protein (designated vac/G2 Afl2) (data not shown).  Clonal cell lines showing
G2 specificity were chosen for further analysis.  Cell lines were courteously provided by
Zachary Scott and John Cruz.
T-Cell Line Maintenance
T-cell lines were maintained at 37° C, 6.0% CO2 in AIM-V medium (Life
Technologies) supplemented with 15% heat-inactivated fetal bovine serum (FBS) (Life
Technologies) and recombinant human interleukin-2 (IL-2), 30 units/ml (Collaborative
Biomedical Products).  Every two weeks cell lines were stimulated with an anti-CD3
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monoclonal antibody, 12F6 at 0.1 µg/ml and gamma-irradiated allogeneic PBMC
feeder cells as previously described (Walker et al., 1989; Littaua et al., 1991; Takahashi
et al., 1991).
Sin Nombre Vac/G2Afl2 Recombinant Vaccinia Virus
A vaccinia viral construct containing the 15 preceding amino acids and the first
211 amino acids of the Sin Nombre G2 protein (amino acids 638-863 of the precursor
GPC protein, 226 amino acids total) was created as previously described (Earl and Moss,
1991) and generously provided by Masanori Terajima.  This construct is designated
vac/G2Afl2 (Refer to Figure 3).
Peptide Synthesis
All peptides based on the G2 protein (Figure 5) were synthesized at the Protein
Chemistry Core Facility at the University of Massachusetts Medical Center, under the
direction of Robert Carraway, Ph,D., using an automated Rainin Symphony peptide
synthesizer.
Selection of Target Cells
Two different types of target cells were used, Epstein Barr Virus transformed B-
lymphoblastoid cell lines (BLCLs) or Hmy2-C1R cell lines.
BLCLs can process an antigen (such as the recombinant vaccinia virus), and
present it on their surface in conjunction with a class I HLA antigen.  Also, soluble
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Figure 5.  Synthesized Peptide Sequences.  Panel A shows original peptides made.
Panel B shows truncations of Peptide 3 made following screening of peptides of Panel A.
A.  Overlapping Peptide Truncations of vac/G2Afl2 Protein (20 amino acids)
Peptide           Sequence            Amino Acids
01 MGILLTTELI IWAASADTPL 637-657
02 IWAASADTPL MESGWSDTAH 647-667
03 MESGWSDTAH GVGIIPMKTD 657-677
04 GVGIIPMKTD LELDFALASS 667-687
05 LELDFALASS SSYSYRRKLV 677-697
06 SSYSYRRKLV NPANQEETLP 687-707
07 NPANQEETLP FHFQLDKQVV 697-717
08 FHFQLDKQVV HAEIQNLGHW 707-727
09 HAEIQNLGHW MDGTFNIKTA 717-737
10 MDGTFNIKTA FHCYGECKKY 727-747
11 FHCYGECKKY AYPWQTAKCF 737-757
12 AYPWQTAKCF FEKDYQYETS 747-767
13 FEKDYQYETS WGCNPPDCPG 757-777
14 WGCNPPDCPG VGTGCTACGV 767-787
15 VGTGCTACGV YLDKLRSVGK 777-797
16 YLDGKLRSVGK AYKIVSLKYT 787-807
17 AYKIVSLKYT RKVCIQLGTE 797-817
18 RKVCIQLGTE QTCKHIDVND 807-827
19 QTCKHIDVND CLVTPSVKVC 817-837
20 CLVTPSVKVC MIGTISKLQP 827-847
21 MIGTISKLQP GDTLLFLGPL 837-857
22 GDTLLFLGPL EQGGIILN 847-865
B. Truncations of Peptide 03.  Aligned according to consensus sequence.
(9-14 amino acids)
Peptide        Sequence               Amino Acids
03     MESGWSDTAHGVGIIPMKTD 657-676
3A ESGWSDTAHGVGII 658-671
3B    WSDTAHGVGIIPMK 661-674
3C       TAHGVGIIPMKTD 664-676
3D     SDTAHGVGI 662-670
3E       TAHGVGIIP 664-672
3F        AHGVGIIPM 665-673
3G         HGVGIIPMK 666-674
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antigen (such as the peptides) can be bound to the cell surface in conjunction with the
HLA antigen (Coleman, Lombard and Sicard, 1992).  Autologous or allogeneic BLCL
lines were selected as target cells depending on the experiment performed.  To define the
epitope, autologous BLCL lines were used to ensure matching class I HLAs.  To
determine HLA restriction, allogeneic BLCL lines were used which were partially HLA
matched in order to determine which HLA allele was restricting the recognition of the
epitope (VanEpps, Schmaljohn, and Ennis, 1999)
Hmy2-C1R is a human plasma cell line lacking endogenous HLA-A and HLA-B
antigens (Storkus et al, 1987).  This cell line was transfected with either B35.01 or
B35.02 as described (Hayashi, et al., 1989; Ooba, et al., 1989).  These cell lines were
kindly provided by Dr. Masafumi Takaguchi.
Preparation of Target Cells
Virus infected target cells were prepared by infecting either BLCLs or Hmy2-
C1R cell lines with the vac/G2 Afl2 virus at a multiplicity of infection (M.O.I) of 15 for 1
hour at 37° C.  Infected cells were then diluted in 1 ml of RPMI 1640 supplemented with
10% FBS and incubated at 37° C for approximately 14 hours before being 51Cr labeled.
51Cr labeling of cells was performed by incubating target cells with 0.25 mCi of
51Cr (in the form of Na251CrO4) in 100 µl of RPMI 1640/10% FBS for 1 hour at 37° C.
After the target cells were 51Cr labeled, they were washed three times and resuspended at
1.5 X 104/ml in RPMI 1640 supplemented with 10%  heat-inactivated FBS.
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Peptide pulsed targets were prepared by incubating uninfected 51Cr labeled cells
(either BLCLs or Hmy2-C1R) with the indicated concentration of peptides for 30 minutes
before effectors were added.
Cytotoxic T-Cell (CTL) Assay  (51Cr Release Assay)
Cytotoxic T-cell (CTL) 51Cr release assays were performed in 96-well round
bottom plates as previously described using either BLCLs or Hmy2-C1R cell lines as
target cells (Ennis, et al., 1997; Littaua et al., 1991; Walker et al., 1989).  Target cells
were prepared as described above, and 1.5 X 103 cells were added to each well of a 96
well round bottom plates in 100µl. 100 µl of effector cells (T cell lines) were added at
Effector:Target (E:T) ratios as indicated.  Each sample was assayed in triplicate.
Plates were incubated at 37°C for 4 hours.  The media was then harvested from
individual wells using the Skatron supernatant collection system (Skatron Instruments)
and counts per minute (cpm) for each sample were measured using a gamma counter.
Specific lysis was calculated as (experimental release-spontaneous
release)/(maximum release-spontaneous release) X 100 (VanEpps, Schmaljohn and
Ennis, 1999).  Negative controls were uninfected/unpulsed targets.  Spontaneous lysis
(determined by spontaneous release/maximum release X 100) was <30% for most assays.
RNA Isolation
RNA isolation was performed from 1 X 107 BLCLs from Donor NM3 as
specified by the UltraSpec RNA Isolation kit (Biotecx Laboratories, Inc.).  Briefly, cell
pellets were lysed with UltraSpec solution, chloroform was added, and the sample was
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incubated on ice for 5 minutes.  After centrifugation for 15 minutes at 12,000g (at 4°
C), the aqueous phase was collected and an equal volume of isopropanol was added.  The
sample was placed on ice for 10 minutes then centrifuged for 10 minutes at 12,000g (at
4° C).  The sample was then washed twice with 1 ml of 75% ethanol by vortexing and
then centrifuging for 5 minutes at 7,500g (at 4° C).  The RNA pellet was then air dried
and resuspended in diethyl pyrocarbonate (DEPC) treated water.
cDNA Synthesis
Complementary DNA was synthesized from total RNA.  2 µg of RNA was added
to 45 µl of  DEPC treated water and 0.5 µg of oligo dT and incubated at 72° C for 2
minutes, then placed at 37° C for 5 minutes.  The sample, 100 Units of RNAse Inhibitor
(Pharmacia Biotech), 1X reaction buffer, 2 mM dNTP, and 500 Units of Moloney murine
leukemia virus (MMLV) reverse transcriptase (Life Technologies) were placed in a 1.5
ml Eppendorf tube in a final volume of 100 µl.  The reaction mixture was incubated at
37° C for 60 minutes then 95° C for 10 minutes.
Polymerase Chain Reaction (PCR)
PCR was performed on the cDNA to isolate the HLA-B cDNA as previously
described (Ennis et al., 1990, Little and Parham, 1991) by use of the GeneAmp kit and a
DNA thermal cycler (Perkin-Elmer).  The reaction mixture included 1 µl of cDNA, 25
pmol of primer 5P2T (specific for class I HLA molecules), 25 pmol of primer 3B
(specific for HLA-B), 1X XLBII buffer, 2 units of r Tth DNA polymerase, 0.8 mM
dNTP, and 0.8 mM  Mg(OAc)2 in 100 µl.  Primer sequences are shown in Figure 6.  60
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µl of mineral oil was added before the tube was placed in the thermal cycler.  The
thermal cycler’s program was as follows:  60 seconds at 94° C, 30X (30 seconds at 94° C
then 5 minutes at 65° C), 72° C for 10 minutes.  PCR product was detected by
electrophoresis.
Gel Electrophoresis
A 1% agarose gel was made in TAE buffer with ethidium bromide (final
concentration 0.1 mg/ml) .  The gel was placed in TAE buffer with ethidium bromide
(final concentration approximately 0.05 mg/ml).  A øX174/Hae III digest was used as
DNA size markers.  5 µl of PCR product was run with an equal amount of 2X loading
buffer (0.083% bromophenol blue, 0.83% xylene cyanol FF, 5% Ficoll).  A PCR product
previously determined to be a B35.02 sequence was loaded as a positive control.  The gel
was run at 100 V for approximately 30 minutes.
Purification of PCR Product
The PCR product was purified with the Qiagen QIAquick Purification Kit using
the microcentrifuge method.  Briefly, 5 volumes of Buffer PB (250 µl) was added to 1
volume (50 µl) of PCR reaction.  The sample was placed in a QIAquick column and
centrifuged for 60 seconds at 10,000 g.   The flow through was discarded, and the column
was washed with 750 µl of Buffer PE and centrifuged for 60 seconds at 10,000 g.  DNA
was eluted into a clean 1.5 ml centrifuge tube with 30 µl of 10mM Tris-HCl pH 8.5 by
letting stand for 1 minute and then centrifuging at  10,000 g.  Purification was confirmed
by electrophoresis.
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Figure 6.  DNA Sequence of Priming and Sequencing Oligonucleotides.  A.
Schematic of HLA-B PCR product showing PCR primers (large arrows), sequencing
primers (small arrows), and exon boundaries (vertical lines).  Arrowheads are at the 3’
hydroxyl end of each oligonucleotide primer and point in the direction of polymerase
extension.  B.  Sequences of priming and sequencing oligonucleotides.  Underlined
regions indicate enzyme cutting sites listed above the region.  Sequencing
oligonucleotides S are derived from the sense strand, and N from the antisense strand.
(modified from Ennis et al., 1990; Little and Parham, 1991)
A.
HLA-5P2 3S
⇒    →
 ← ⇐
 3N        HLA-3B
           EXON 1        EXON 2                EXON 3                   EXON 4                 EXON 5              EXONS 6-8
B.
Priming oligonucleotides
Primer Encompasses 5’                                                                 3’
Sal I
HLA-5P2 5’ untranslated region gggcgtcgacggactcagaatctccccagacgcgag
       Hind III
HLA-3B 3’ untranslated region            ccgcaagcttctggggaggaaacacaggtcagcatgggaac
Sequencing oligonucleotides
Primer Encompasses 5’                                    3
3S exon 3, nucleotides 429-450 cggcaaggattacatcgccctg
3N exon 3, nucleotides 429-450 cagggcgatgtaatccttgccg
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Sequencing of DNA
DNA sequencing was done by the Nucleic Acid Facility at the University of
Massachusetts Medical Center, using the ABI PRISM Dye Terminator Cycle Sequencing
Ready Reaction Kit (Perkin Elmer).  Primers used were 3S and 3N (Figure 6).  Products
were electrophoresed on a 4.75% poly-acrylamide gel, and sequences were analyzed
using ABI 373 stretch Automated Sequencer, and ABI Prism Sequencing 2.1.1 (ABI)
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Results
G2Afl2 Peptide Screening
Overlapping peptides of 20 amino acids in length were made spanning the entire
G2 Afl2 region.  Each of these peptides overlapped by ten amino acid regions at the
amino and carboxy ends (Figure 5A).
These peptides were screened in two separate CTL assays, at 25 µg/ml, with a
CD8+ T cell line, 3c12, isolated from donor NM3 at an Effector:Target (E:T) ratio of
10:1.  The viral construct vac/G2Afl2 was used as a positive control to show G2 protein
cytotoxic specificity.  It is important to note that a negative lysis is equivalent to 0.0%,
and any lysis of greater than 100% is equivalent to 100%.
The 3c12 cell line was shown to specifically lyse autologous BLCLs infected with
the vac/G2Afl2 virus at up to 66.5%, and peptide 03 pulsed autologous BLCLs at
133.5%. However uninfected/unpulsed autologous BLCLs were lysed at only up to 8.9%,
and autologous BLCLs pulsed with peptides 01, 02, and 04-22 ranged from 0-12.8%.
This indicates cell line 3c12 has cytotoxic specificity for Peptide 03 (Table 1).
Since neither peptide 02 nor peptide 04 was recognized, it was determined that the
area containing the G2 epitope would be a sequence that was only completely contained
in peptide 03.
Cell lines 10K and 10c27 were also tested in a CTL assay against autologous
BLCLs pulsed with peptide 02, 03, or 04 with vac/G2Afl2 infected autologous BLCLs as
a positive control to determine if other NM3 cell lines would also recognize this peptide
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Table 1.  CD8+ Cell line 3c12 (Donor NM3) Shows Cytotoxic Specificity for the
Recognition of Peptide 03.  E:T = 10:1, Peptide concentrations were 25 µg/ml.
Experiment # Target- NM3 BLCLs % Lysis
1 Vac/G2Afl2 66.5
1 Uninfected/Unpulsed 6.8
2 vac/G2Afl2 57.0
2 Uninfected/Unpulsed 8.9
2 01 (aa 637-657) 2.3
2 02 (aa 647-667) 2.3
2 03 (aa 657-677) 133.5
2 04 (aa 667-687) 6.8
2 05 (aa 677-697) 3.7
1 06 (aa 687-707) 7.3
1 07 (aa 697-717) 12.4
2 08 (aa 707-727) -0.6
2 09 (aa 717-737) 4.9
2 10 (aa 727-747) 7.4
2 11 (aa 737-757) 5.1
2 12 (aa 747-767) 4.1
2 13 (aa 757-777) -0.6
2 14 (aa 767-787) 2.3
1 15 (aa 777-797) 12.8
1 16 (aa 787-807) 4.8
2 17 (aa 797-817) 8.3
2 18 (aa 807-827) 0.7
2 19 (aa 817-837) 3.7
1 20 (aa 827-847) 1.9
1 21 (aa 837-857) 3.2
1 22 (aa 847-867) 0.6
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 (Table 2).  Both 10K and 10c27 were shown to specifically lyse peptide 03-pulsed
BLCLs (specific lysis 96-99%).
Screening of Peptide 03 Truncations
Once it was determined that the epitope being recognized was contained
exclusively in peptide 03, three 14 amino acids peptides were made based on the
sequence of peptide 03 (designated 3A, 3B, and 3C) (Figure 5B).  These truncations were
screened in a CTL assay at 25 µg/ml, with cell lines 10K and 10c27 at an E:T of 10:1.
Autologous BLCLs pulsed with each peptide at 25 µg/ml were used as the targets.
Autologous BLCLs pulsed with peptide 03 at 25 µg/ml was used as the positive control,
and unpulsed autologous BLCLs were the negative control (Table 3).
This assay showed that both 10K and 10c27 recognize peptide 3B and peptide 3C.
That indicates that the epitope that the cell lines are recognizing is located in the
overlapping region of peptides 3B and 3C.  This region corresponds to amino acids 664-
674 of the precursor GPC protein.
Screening of Overlapping Areas of Peptides 3B and 3C
Three nine amino acid long peptides were then made of the region which overlaps
in peptides 3B and 3C. These peptides were designated 3E, 3F and 3G based on their
starting amino acids (sequences are shown in Figure 5B).  Another nine amino acid long
peptide was made extending to the left of the overlapping portions of 3B and 3C.  This
peptide was designated 3D (sequence shown in Figure 5B).
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Table 2.  CD8+ Cell Lines 10K and 10c27 (Donor NM3) Show Cytotoxic Specificity
for the Recognition of Peptide 03.  E:T = 10:1, Peptide concentrations were 25 µg/ml.
% Lysis
Target- NM3 BLCLs 10K 10c27
vac/G2Afl2 84.4 93.8
Uninfected/Unpulsed 1.0 2.6
02 (aa 647-667) -2.8 -0.1
03 (aa 657-677) 96.0 98.9
04 (aa 667-687) -0.4 1.0
Table 3.  CD8+ Cell Lines 10K and 10c27 (Donor NM3) Show Cytotoxic Specificity for
the Overlapping Portion of Peptides 3B and 3C.  E:T = 10:1, Peptide concentrations were
25 µg/ml.
% Lysis
Target-NM3 BLCLs Amino Acid Sequence 10K 10c27
Uninfected/Unpulsed 1.0 2.6
03 (aa 657-677) MESGWSDTAHGVGIIPMKTD 96.0 98.9
3A (aa 658-671)  ESGWSDTAHGVGII -0.2 -1.1
3B (aa 661-674)     WSDTAHGVGIIPMK 88.3 92.3
3C (aa 664-676)        TAHGVGIIPMKTD 83.3 81.7
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A CTL assay with cell lines 10K and 10c27 was done with these peptides using
autologous BLCLs pulsed with the peptides at a concentration of 25 µg/ml.  Autologous
BLCLs pulsed with peptide 03 at a concentration of 25 µg/ml were used as a positive
control, and unpulsed autologous BLCLs were used as a negative control (Table 4).
This assay showed that cell line 10K recognized peptide 3E exclusively.
However, cell line 10c27 recognized both 3E and 3F at a concentration of 25 µg/ml.  Cell
line 10c27 also seems to have greater avidity for the peptide than cell line 10K, since the
percent specific lysis is higher.
Neither peptide 3D (data not shown) nor peptide 3F were recognized by either
cell line 10K or 10c27 at a concentration of 25 µg/ml.
Overview of Recognition of Peptide 03 Truncations
An overview of the results of experiments using truncations of peptide 03
indicates which amino acids are essential for epitope recognition  (Table 5).  Cell line
10K only recognizes peptides containing the entire nine amino acid sequence of peptide
3E (aa 664-672).  In contrast, cell line 10c27 recognizes peptide truncations which
contain only amino acids 665-672.  The lack of response of both cell lines to peptide 3A
indicates that the proline at position 672 is an essential part of the epitope recognized by
both cell lines.  The lack of response of cell line 10K to peptide 3F indicates that the
threonine at position 664 is an essential part of the epitope recognized by this cell line.
However, since 10c27 does recognize this peptide, this indicated that the threonine at
position 664 is not an essential part of the epitope for this cell line.  The lack of
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Table 4.  CD8+ Cell Line 10K shows Cytotoxic Specificity for peptide 3E, but CD8+
Cell Line 10c27 Shows Cytotoxic Specificity for Both Peptides 3E and 3F.  E:T = 10:1,
Peptide concentrations were 25 µg/ml.
% Lysis
Target-NM3 BLCLs Amino Acid Sequence 10K 10c27
Uninfected/Unpulsed 0.9 -1.6
03 (aa 657-677) MESGWSDTAHGVGIIPMKTD 74.5 102.7
3E (aa 664-672)        TAHGVGIIP 51.4 93.5
3F (aa 665-673)         AHGVGIIPM 5.4 99.8
3G (aa 666-674)          HGVGIIPMK -0.8 2.5
Table 5.  Peptides to Which Cell Lines 10K and 10c27 Show a Positive Response.
Amino acids which are shown to be essential for recognition in at least one cell line are
indicated by bold face in the peptide sequence which is recognized.
Recognition
by Cell Line
at 25 µg/ml
Peptide Sequence 10K 10c27
03 (aa 657-677) MESGWSDTAHGVGIIPMKTD + +
3A (aa 658-671)  ESGWSDTAHGVGII - -
3B (aa 661-674)     WSDTAHGVGIIPMK + +
3C (aa 664-676)        TAHGVGIIPMKTD + +
3D (aa 662-670)      SDTAHGVGI - -
3E (aa 664-672)        TAHGVGIIP + +
3F (aa 665-673)         AHGVGIIPM - +
3G (aa 666-674)          HGVGIIPMK - -
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recognition of peptide 3G of both cell line 10K and 10c27 indicates that the alanine at
position 665 is essential for recognition for both cell lines.
Dose Dependent Recognition of Peptides 3E and 3F
A dose dependent response for peptide 3E (aa 664-672) is shown for both cell
lines 10K and 10c27 at an E:T of 10:1 (Figure 7 and Table 6).  Peptide 3E is maximally
recognized by these cell lines at concentrations greater than or equal to 0.25µg/ml.  The
cells lines also show partial recognition down to 2.5 ng/ml, at which point the peptide is
then at a concentration too low to be recognized.
However, only cell line 10c27 exhibits a dose dependent response for peptide 3F
(aa 665-673), whereas cell line 10K does not recognize peptide 3F at any concentration
(Figure 8 and Table 7).  The recognition of peptide 3F by cell line 10c27 is strong at
concentrations as low as 25 ng/ml, with partial recognition at 2.5 ng/ml.
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Figure 7.  Both Cell Lines 10K and 10c27 Exhibit a Dose Response for Peptide 3E
Table 6.  Dose Dependent Response of Cell Lines 10K and 10c27 to Peptide 3E.  Target
cells are NM3 BLCLs pulsed with peptide 3E at the concentrations indicated.  The E:T
ratio was 10:1.  Peptide 03 pulsed targets were included as a positive control, and
unpulsed targets were included as a negative control.  Bold face indicates strong
recognition, and underlining indicates slight recognition.
% Lysis of Target NM3 BLCLs
Peptide 03 Unpulsed 3E
Conc. 25
µg/ml
25
µg/ml
2.5
µg/ml
0.25
µg/ml
25
ng/ml
2.5
ng/ml
0.25
ng/ml
25
pg/ml
10K 45.5 -2.7 42.2 41.8 30.6 5.6 -3.4 -3.7 -0.9
10c27 76.4 -2.2 63.4 64.5 56.0 23.5 10.0 -2.1 -3.6
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Figure 8.  Cell Line 10c27 Exhibits a Dose Response for Peptide 3F
Table 7.  Dose Dependent Response of Cell Lines 10K and 10c27 to Peptide 3F.  Target
cells are NM3 BLCLs pulsed with peptide 3F at the concentrations indicated.  The E:T
ratio was 10:1.  Peptide 03 pulsed targets were included as a positive control, and
unpulsed targets were included as a negative control.  Bold face indicates strong
recognition and underlining indicates slight recognition.
% Lysis of Target NM3 BLCLs
Peptide 03 Unpulsed 3F
Conc. 25
µg/ml
25
µg/ml
2.5
µg/ml
0.25
µg/ml
25
ng/ml
2.5
ng/ml
0.25
ng/ml
25
pg/ml
10K 45.5 -2.7 6.4 -3.9 -3.2 -1.5 -2.1 -5.1 -5.5
10c27 76.4 -2.2 56.8 65.5 69.1 45.6 9.7 0.1 -2.7
Dose Dependent Response Curve of Cell Lines 10K and 
10c27 to Peptide 3F
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HLA Restriction of Vac/G2Afl2 Recognition
To determine which HLA antigen was restricting the recognition of the epitope
contained in the vac/G2Afl2 construct, NM3 cell line 10F was screened in CTL assays
against vac/G2Afl2 infected BLCLs from various donors sharing at least one HLA Class
1 allele (Table 8).  Cell line 10F recognizes Donor 9 (CCL011) who shares only HLA-
B35, indicating this is the restricting HLA antigen.  Cell line 10F also recognizes Donor 3
(3099), Donor 5 (MB) and Donor 8 (CCL002) who share HLA-A2, HLA-B35 and HLA-
C4.  Donor 4 (KS), who shares HLA-B35 and HLA-C4, is also recognized.   Although all
allogeneic target cells cell line 10F recognizes express the HLA-B35 allele, cell line 10F
does not recognize every target expressing HLA-B35.  Therefore, the recognized epitope
is restricted by a specific HLA-B35 subtype.  It is also shown that the restricting subtype
for recognition is not HLA-B35.02, since Donor 1 (JC) is not recognized and is known to
be HLA-B35.02.
Determination of HLA-B35 Subtype of NM3
To define the HLA-B35 subtype of NM3, RNA was isolated from the NM3
BLCLs, cDNA was made, and PCR was performed using HLA-B specific primers.  The
presence of a PCR product was confirmed by electrophoresis.  After purification, the
PCR product was sequenced.  Comparison of the sequence to known B35 subtypes show
that donor NM3 has HLA-B35.01 (Appendix I).  It is also clear that NM3 is homozygous
for B35.01, since direct sequencing of the PCR product showed that there was only one
HLA-B sequence present.
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Table 8.  Recognition of Allogeneic BLCLs Expressing the Sin Nombre Virus G2
Protein.  HLA alleles shared by both target cells and NM3 are shown.  Subtypes, if
known, are designated by listing after the decimal point.  All target cells (with the
exception of the uninfected NM3 negative control cells) were infected with vac/G2Afl2.
Alleles shared are shown.  Alleles which are shared are bold if there was a cytotoxic
response from at least one cell line.  E:T = 10.
HLA Alleles Expressed % Lysis
Target HLA-A HLA-B HLA-C 10F
Experiment 1 NM3 2 35 4 58.7
NM3/uninf. -0.8
Donor 1 (JC) 35.02 4 -4.7
Donor 2 (Va12) 35 4 0.2
Donor 3 (3099) 2 35 4 59.3
Donor 4 (KS) 35 4 58.7
Donor 5 (MB) 2.1 35 4 44.7
Donor 6 (GJ) 2 -1.7
Experiment 2 NM3 2 35 4 78.4
NM3/uninf. 2.8
Donor 7 (CCL051) 2 4 10.2
Donor 8 (CCL002) 2 35 4 88.8
Donor 9 (CCL011) 35 108.5
Donor 10 (CCL031) 35 4 9.1
Donor 11 (CB) 2 35 4 4.5
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Recognition of Peptide 03 by CTL Lines 10K and 10c27 is HLA-B35.01 Restricted
Once the donor, NM3, was determined to have the HLA-B35.01 gene, it was
possible to confirm that this was, in fact, the HLA allele restricting recognition of the G2
epitope recognized by cell line 10K, using target cells only expressing various forms of
HLA-B35.  The cell lines used were HMY-C1R cells which either expressed only HLA-
B35.01, only HLA-B35.02 or no HLA-A or HLA-B (HMY-C1R control).  NM3 BLCLs
were used as a positive control.  Unpulsed target cells were included for each type of
target as a negative control.  The E:T was 10:1.  This CTL assay shows that cell line 10K
is clearly restricted by HLA-B35.01.  Cell line 10c27 was also apparently restricted by
HLA-B35.01.  However, at the peptide concentration of 25µg/ml used in this assay, there
was also significant lysis of the HMY-C1R B35.02 and control cells (Table 9).
HLA-B35.01 restriction of cell line 10c27 was further confirmed in a CTL assay
using a lower E:T ratio (5:1) and lower peptide concentrations (2.5 µg/ml-2.5 ng/ml).
Peptides 3E and 3F were used, since they had been shown to contain the optimal epitope
(Table 10).  This assay did show that cell line 10c27 is B35.01 restricted.  It is important
to note that the lower levels of lysis are due to the lowered E:T ratio and lowered peptide
concentrations and do not indicate that the cell lines are not lysing the targets.
30
Table 9.  Cell Line 10K Recognizes a HLA-B35.01 Restricted Epitope on Peptide 03.
Recognition by cell line 10c27 also seems to be HLA-B35.01 restricted, but high
background lysis require confirmation.  E:T = 10:1.  Peptide concentrations were 25
µg/ml.
% Lysis
Target 10K 10c27
NM3/peptide 03 67.3 85.3
NM3/unpulsed -2.6 -0.2
HMY-C1R B35.01/peptide 03 87.0 105.7
HMY-C1R B35.01/unpulsed -1.1 0.4
HMY-C1R B35.02/peptide 03 18.2 56.7
HMY-C1R B35.02/unpulsed 1.2 1.4
HMY-C1R control/peptide 03 15.3 48.0
HMY-C1R control/unpulsed -4.1 -2.4
Table 10.  Recognition of Peptides 3E and 3F by Cell Line 10c27 is HLA-B35.01
Restricted. E:T = 5:1
% Lysis by Cell Line 10c27
Unpulsed Peptide 3E Peptide 3F
Targets 2.5
µg/ml
0.25
µg/ml
25
ng/ml
2.5
ng/ml
2.5
µg/ml
0.25
µg/ml
25
ng/ml
2.5
ng/ml
HMY-C1R
B35.01
0.8 16.2 24.6 23.1 0.5 18.0 30.9 23.5 12.3
HMY-C1R
B35.02
-3.2 5.2 1.2 -0.6 -0.1 6.6 1.3 0.3 0.4
HMY-C1R
control
0.0 8.0 -1.6 -3.6 -4.9 2.6 -2.6 -4.6 -6.7
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Discussion
Definition of B35.01 Restricted Epitopes in the Sin Nombre Virus G2 Protein
Studies presented here have defined the first CD8+ cytotoxic T cell epitopes to be
located in the Sin Nombre virus G2 protein.  CTL assays with peptide pulsed targets have
shown that NM3 T cell line 10K recognizes the nine amino acid sequence TAHGVGIIP
(aa 664-672) of the G2 protein of the Sin Nombre hantavirus.  Another NM3 T cell line,
10c27, recognizes the eight amino acid sequence AHGVGIIP (aa 665-672) of the Sin
Nombre virus G2 protein.  Both of these epitopes have been shown to be restricted by
HLA B35.01 based on PCR analysis of NM3 HLA genes and CTL assays with HMY-
C1R cells expressing HLA-B35 alleles.
New Motif for B35.01
The epitopes that were defined for these Sin Nombre virus specific cell lines do
not fit the current predictions for HLA-B35 motif.  The motifs that are predicted are
epitopes which contain the amino acid Proline at position 2 of the epitope, and amino
acids Tyrosine, Phenylalanine, Methionine, Leucine, or Isoleucine at position 9 of the
epitope (Rammensee, Friede and Stevanovic, 1995).  The nine amino acid epitope that
was described here contains amino acid Alanine at position 2 and amino acid Proline at
position 9.  Using the search strategies available at the BIMAS HLA Peptide Binding
Predictions website (http://bimas.dcrt.nih.gov/molbio/hla_bind/), the epitope that was
defined was not the best match in the entire M segment protein.  In fact, this program,
which ranks possible epitopes by their predicted halftime of dissociation, indicates that
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this sequence is one of the least likely to be recognized (Parker, Bednarek and Coligan,
1994).  This indicates that the predicted motifs may need to be revised.
Future Work
The eight amino acid peptide that is believed to be the epitope recognized by cell
line 10c27 needs to be synthesized.  Once this peptide is tested, the exact minimum
epitope recognized by cell line 10c27 will be conclusively defined.
Both cell lines should also be tested against G2 proteins of other hantaviruses to
ascertain if there is any cross reactivity.  A preliminary search on the Entrez database
(http://www.ncbi.nlm.nih.gov/Entrez/), showed that other hantavirus G2 proteins do not
contain the exact epitope recognized by the cell lines, however there may be similar
amino acid sequences located in the G2 proteins of other hantaviruses which could be
recognized.  The recognized peptides should likewise be screened with T cell lines
isolated from other patients infected with hantavirus types to determine whether they can
be recognized in a cross reactive fashion.
Also, the background lysis that was shown in screening of cell line 10c27 against
HMY-C1R targets at high E:T ratios should be further analyzed to determine if 10c27
might be slightly cross-reactive with other subtypes of B35.
Cytotoxic T cell lines should be isolated and characterized from other patients
who have had Sin Nombre virus infection.  This would make it possible to define other
epitopes which may be restricted by different HLA alleles.
This information can be used to help determine the exact pathogenesis of
Hantavirus Pulmonary Syndrome.  Since patients with different HLA alleles seem to
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react to the virus differently, it would be interesting to compare the patients’ disease
progress to the response that is obtained in vitro.  Specifically, current research indicates
that patients who express the HLA-B35 allele tend to have more severe HPS (Koster et
al., 1998).  It would be interesting to determine what exactly is causing an increase in the
severity of HPS in patients expressing HLA-B35, and whether this specific epitope may
have a part in this reaction.
The cytokine production of these cell lines should also be determined.  Previous
studies have indicated that T cells producing high amounts of cytokines could cause
capillary leaking in the lungs, a symptom characteristic of HPS (Mori et al., 1999).
Finally, after defining other T cell epitopes of Sin Nombre virus, a vaccine could
conceivably be made by combining different viral peptides in a harmless construct.  This
vaccine should be able to induce a cytotoxic T cell response in any person having the
restricting HLA molecules of the epitopes used.  In fact, if there are several epitopes
which can cause a cross reactive response for different viruses and also have different
HLA restrictions, it could be possible to create one vaccine for protection against more
than one type of hantavirus.
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Appendix I:  Comparison of NM3 HLA-B35 Sequence to
Known B35 Sequences
Sequences were obtained from (Mason and Parham, 1998).  Alignment done with Align
Plus 3.0 (Scientific and Educational Software).  Molecules were shortened to contain
only the region spanned by the NM3 HLA-B35 sequenced product.  The large region,
which is not present in NM3, corresponds to the region in which the primers overlapped.
.     indicates base is same as reference molecule (NM3)
- indicates base not present
n    indicates base was undetermined
Reference molecule:   NM3                1 -   640   (  640 bps)  Homology
       Sequence  2:   B3501.SEQ          1 -  1087   ( 1087 bps)      98%
       Sequence  3:   B3502.SEQ          1 -  1087   ( 1087 bps)      98%
       Sequence  4:   B3503.SEQ          1 -  1090   ( 1090 bps)      98%
       Sequence  5:   B3504.SEQ          1 -  1089   ( 1089 bps)      98%
       Sequence  6:   B3505.SEQ          1 -  1089   ( 1089 bps)      98%
       Sequence  7:   B3506.SEQ          1 -  1089   ( 1089 bps)      98%
       Sequence  8:   B3507.SEQ          1 -  1089   ( 1089 bps)      98%
       Sequence  9:   B3508.SEQ          1 -  1089   ( 1089 bps)      98%
       Sequence 10:   B35091.SEQ         1 -  1089   ( 1089 bps)      98%
       Sequence 11:   B35092.SEQ         1 -   547   (  547 bps)      74%
       Sequence 12:   B3510.SEQ          1 -   526   (  526 bps)      72%
       Sequence 13:   B3511.SEQ          1 -   526   (  526 bps)      72%
       Sequence 14:   B3512.SEQ          1 -   526   (  526 bps)      72%
       Sequence 15:   B3513.SEQ          1 -   546   (  546 bps)      74%
       Sequence 16:   B3514.SEQ          1 -   546   (  546 bps)      74%
       Sequence 17:   B3516.SEQ          1 -  1089   ( 1089 bps)      98%
       Sequence 18:   B3517.SEQ          1 -   546   (  546 bps)      74%
       Sequence 19:   B3518.SEQ          1 -   546   (  546 bps)      74%
       Sequence 20:   B3519.SEQ          1 -   546   (  546 bps)      75%
       Sequence 21:   B3520.SEQ          1 -   546   (  546 bps)      75%
       Sequence 22:   B3521.SEQ          1 -   546   (  546 bps)      75%
       Sequence 23:   B3522.SEQ          1 -   546   (  546 bps)      74%
       Sequence 24:   B3523.SEQ          1 -   546   (  546 bps)      75%
       Sequence 25:   B3524.SEQ          1 -   546   (  546 bps)      75%
       Sequence 26:   B3525.SEQ          1 -   546   (  546 bps)      75%
Alignment type:       Global DNA
Parameters:           Mismatch 2;  Open Gap 4;  Extend Gap 1
NM3          (     1) -ccgccatgtcccggcccggccgnggggagccccgnttcatcgcagtggg
B3501.SEQ    (   101) -......................c...........c..............
B3502.SEQ    (   101) -......................c...........c..............
B3503.SEQ    (   101) a......................c...........c..............
B3504.SEQ    (   101) -......................c...........c..............
B3505.SEQ    (   101) -......................c...........c..............
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B3506.SEQ    (   101) -......................c...........c..............
B3507.SEQ    (   101) -..................t...c...........c..............
B3508.SEQ    (   101) -......................c...........c..............
B35091.SEQ   (   101) -......................c...........c..............
B35092.SEQ   (    28) -......................c...........c..............
B3510.SEQ    (    28) -......................c...........c..............
B3511.SEQ    (    28) -......................c...........c..............
B3512.SEQ    (    28) -......................c...........c..............
B3513.SEQ    (    28) -......................c...........c..............
B3514.SEQ    (    28) -......................c...........c..............
B3516.SEQ    (   101) -......................c...........c..............
B3517.SEQ    (    28) -......................c...........c..............
B3518.SEQ    (    28) -......................c...........c..............
B3519.SEQ    (    28) -......................c...........c..............
B3520.SEQ    (    28) -......................c...........c..............
B3521.SEQ    (    28) -......................c...........c..............
B3522.SEQ    (    28) -......................c...........c..............
B3523.SEQ    (    28) -......................c...........c..............
B3524.SEQ    (    28) -......................c...........c..............
B3525.SEQ    (    28) -......................c...........c..............
NM3          (    50) cnacgtggacgacacccagttcgtgaggttngacagcgacgccgcgagtc
B3501.SEQ    (   150) .t............................c...................
B3502.SEQ    (   150) .t............................c...................
B3503.SEQ    (   151) .t............................c...................
B3504.SEQ    (   150) .t............................c...................
B3505.SEQ    (   150) .t............................c...................
B3506.SEQ    (   150) .t............................c...................
B3507.SEQ    (   150) .t............................c...................
B3508.SEQ    (   150) .t............................c...................
B35091.SEQ   (   150) .t............................c...................
B35092.SEQ   (    77) .t............................c...................
B3510.SEQ    (    77) .t............................c...................
B3511.SEQ    (    77) .t............................c...................
B3512.SEQ    (    77) .t............................c...................
B3513.SEQ    (    77) .t............................c...................
B3514.SEQ    (    77) .t............................c...................
B3516.SEQ    (   150) .t............................c...................
B3517.SEQ    (    77) .t............................c...................
B3518.SEQ    (    77) .t............................c...................
B3519.SEQ    (    77) .t............................c...................
B3520.SEQ    (    77) .t............................c...................
B3521.SEQ    (    77) .t............................c...................
B3522.SEQ    (    77) .t............................c...................
B3523.SEQ    (    77) .t............................c...................
B3524.SEQ    (    77) .t............................c...................
B3525.SEQ    (    77) .t............................c...................
NM3          (   100) cgaggacggagccccgggcgccatggatagagcaggaggggccggagtat
B3501.SEQ    (   200) ..................................................
B3502.SEQ    (   200) ..................................................
B3503.SEQ    (   201) ..................................................
B3504.SEQ    (   200) ..................................................
B3505.SEQ    (   200) ..................................................
B3506.SEQ    (   200) ..................................................
B3507.SEQ    (   200) ..................................................
B3508.SEQ    (   200) ..................................................
B35091.SEQ   (   200) ..................................................
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B35092.SEQ   (   127) ..................................................
B3510.SEQ    (   127) ..................................................
B3511.SEQ    (   127) ..................................................
B3512.SEQ    (   127) ..................................................
B3513.SEQ    (   127) ..................................................
B3514.SEQ    (   127) ..................................................
B3516.SEQ    (   200) ..................................................
B3517.SEQ    (   127) ..................................................
B3518.SEQ    (   127) ..................................................
B3519.SEQ    (   127) ......a......g....................................
B3520.SEQ    (   127) ..................................................
B3521.SEQ    (   127) ..................................................
B3522.SEQ    (   127) ..................................................
B3523.SEQ    (   127) ..................................................
B3524.SEQ    (   127) ..................................................
B3525.SEQ    (   127) ..................................................
NM3          (   150) tgggaccggaacacacagatcttcaagaccaacacacagactnaccgaga
B3501.SEQ    (   250) ..........................................t.......
B3502.SEQ    (   250) ..........................................t.......
B3503.SEQ    (   251) ..........................................t.......
B3504.SEQ    (   250) ..........................................t.......
B3505.SEQ    (   250) ..........................................t.......
B3506.SEQ    (   250) ..........................................t.......
B3507.SEQ    (   250) ..........................................t.......
B3508.SEQ    (   250) ..........................................t.......
B35091.SEQ   (   250) ..........................................t.......
B35092.SEQ   (   177) ..........................................t.......
B3510.SEQ    (   177) .........g.g..............................t.......
B3511.SEQ    (   177) .........g.g..............................t.......
B3512.SEQ    (   177) .........g.g..............................t.......
B3513.SEQ    (   177) .........g.g..............................t.......
B3514.SEQ    (   177) ..........................................t.......
B3516.SEQ    (   250) ..........................................t.......
B3517.SEQ    (   177) ..........................................t.......
B3518.SEQ    (   177) ..........................................t.......
B3519.SEQ    (   177) ..........................................t.......
B3520.SEQ    (   177) ......................c...................t.......
B3521.SEQ    (   177) ..........................................t.......
B3522.SEQ    (   177) ..........................................t.......
B3523.SEQ    (   177) ..........................................t.......
B3524.SEQ    (   177) ..........................................t.......
B3525.SEQ    (   177) ..........................................t.......
NM3          (   200) gagcctgcggaacctgcgcggctactacaaccagagcgaggccgggtctc
B3501.SEQ    (   300) ..................................................
B3502.SEQ    (   300) ..................................................
B3503.SEQ    (   301) ..................................................
B3504.SEQ    (   300) ..................................................
B3505.SEQ    (   300) ..................................................
B3506.SEQ    (   300) ..................................................
B3507.SEQ    (   300) ..................................................
B3508.SEQ    (   300) ..................................................
B35091.SEQ   (   300) ..................................................
B35092.SEQ   (   227) ..................................................
B3510.SEQ    (   227) ..................................................
B3511.SEQ    (   227) ..................................................
B3512.SEQ    (   227) ..................................................
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B3513.SEQ    (   227) ..................................................
B3514.SEQ    (   227) ..................................................
B3516.SEQ    (   300) ..................................................
B3517.SEQ    (   227) ..................................................
B3518.SEQ    (   227) ..................................................
B3519.SEQ    (   227) ..................................................
B3520.SEQ    (   227) ..................................................
B3521.SEQ    (   227) ..................................................
B3522.SEQ    (   227) ..................................................
B3523.SEQ    (   227) ..................................................
B3524.SEQ    (   227) ..................................................
B3525.SEQ    (   227) ..................................................
NM3          (   250) acatcatccagaggatgtatggctgcgacctggggcccgacgggcgc-t-
B3501.SEQ    (   350) ...............................................c.-
B3502.SEQ    (   350) ...............................................-.t
B3503.SEQ    (   351) ...............................................c.-
B3504.SEQ    (   350) ...............................................c.-
B3505.SEQ    (   350) ...c.c.......c.....c...........................c.-
B3506.SEQ    (   350) ...............................................c.-
B3507.SEQ    (   350) ...............................................c.-
B3508.SEQ    (   350) ...............................................c.-
B35091.SEQ   (   350) ...............................................c.-
B35092.SEQ   (   277) ...............................................c.-
B3510.SEQ    (   277) ...............................................c.-
B3511.SEQ    (   277) ...............................................c.-
B3512.SEQ    (   277) ...............................................c.-
B3513.SEQ    (   277) ...............................................c.-
B3514.SEQ    (   277) ...............................................c.-
B3516.SEQ    (   350) ...............................................c.-
B3517.SEQ    (   277) .............c.....c.........g.................c.-
B3518.SEQ    (   277) ...............................................c.-
B3519.SEQ    (   277) ...............................................c.-
B3520.SEQ    (   277) ...............................................c.-
B3521.SEQ    (   277) ...............................................c.-
B3522.SEQ    (   277) ...c.c.......c.....c.........g.......g.........c.-
B3523.SEQ    (   277) ..................t............................c.-
B3524.SEQ    (   277) ...............................................c.-
B3525.SEQ    (   277) ...............................................c.-
NM3          (   298) cctccgcgggcatgaccagtccgc--------------------------
B3501.SEQ    (   399) ........................ctacgacggcaaggattacatcgccc
B3502.SEQ    (   399) .............a......a...ctacgacggcaaggattacatcgccc
B3503.SEQ    (   400) ....................t...ctacgacggcaaggattacatcgccc
B3504.SEQ    (   399) ....................t...ctacgacggcaaggattacatcgccc
B3505.SEQ    (   399) ........................ctacgacggcaaggattacatcgccc
B3506.SEQ    (   399) .............a......t...ctacgacggcaaggattacatcgccc
B3507.SEQ    (   399) ........................ctacgacggcaaggattacatcgccc
B3508.SEQ    (   399) ........................ctacgacggcaaggattacatcgccc
B35091.SEQ   (   399) .............a......a...ctacgacggcaaggattacatcgccc
B35092.SEQ   (   326) .............a......a...ctacgacggcaaggattacatcgccc
B3510.SEQ    (   326) ........................ctacgacggcaaggattacatcgccc
B3511.SEQ    (   326) ........................ctacgacggcaaggattacatcgccc
B3512.SEQ    (   326) ........................ctacgacggcaaggattacatcgccc
B3513.SEQ    (   326) ....................t...ctacgacggcaaggattacatcgccc
B3514.SEQ    (   326) ........................ctacgacggcaaggattacatcgccc
B3516.SEQ    (   399) ........................ctacgacggcaaggattacatcgccc
B3517.SEQ    (   326) ........................ctacgacggcaaggattacatcgccc
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B3518.SEQ    (   326) .............a......a...ctacgacggcaaggattacatcgccc
B3519.SEQ    (   326) ........................ctacgacggcaaggattacatcgccc
B3520.SEQ    (   326) ........................ctacgacggcaaggattacatcgccc
B3521.SEQ    (   326) ........................ctacgacggcaaggattacatcgccc
B3522.SEQ    (   326) .............a......a...ctacgacggcaaggattacatcgccc
B3523.SEQ    (   326) ........................ctacgacggcaaggattacatcgccc
B3524.SEQ    (   326) ........................ctacgacggcaaggattacatcgccc
B3525.SEQ    (   326) ........................ctacgacggcaaggattacatcgccc
NM3          (   322) ---acgaggac-tgagctcctggaccgcggcggacaccgcggctcagatc
B3501.SEQ    (   449) tga........c......................................
B3502.SEQ    (   449) tga........c......................................
B3503.SEQ    (   450) tga........c......................................
B3504.SEQ    (   449) tga........c......................................
B3505.SEQ    (   449) tga........c......................................
B3506.SEQ    (   449) tga........c......................................
B3507.SEQ    (   449) tga........c......................................
B3508.SEQ    (   449) tga........c......................................
B35091.SEQ   (   449) tga........c..c...................................
B35092.SEQ   (   376) tga........c..c.............c........g............
B3510.SEQ    (   376) tga........c......................................
B3511.SEQ    (   376) tga........c......................................
B3512.SEQ    (   376) tga........c......................................
B3513.SEQ    (   376) tga........c......................................
B3514.SEQ    (   376) tga........c......................................
B3516.SEQ    (   449) tga........c......................................
B3517.SEQ    (   376) tga........c......................................
B3518.SEQ    (   376) tga........c..c.............c........g............
B3519.SEQ    (   376) tga........c......................................
B3520.SEQ    (   376) tga........c......................................
B3521.SEQ    (   376) tga........c......................................
B3522.SEQ    (   376) tga........c......................................
B3523.SEQ    (   376) tga........c......................................
B3524.SEQ    (   376) tga........c......................................
B3525.SEQ    (   376) tga........c......................................
NM3          (   368) acccagcgcaagtgggaggcggcccgtgtggcggagcanctgaganccta
B3501.SEQ    (   499) ......................................g......g....
B3502.SEQ    (   499) ......................................g......g....
B3503.SEQ    (   500) ......................................g......g....
B3504.SEQ    (   499) ......................................g......g....
B3505.SEQ    (   499) ......................................g......g....
B3506.SEQ    (   499) ......................................g......g....
B3507.SEQ    (   499) ......................................g......g....
B3508.SEQ    (   499) ......................................g.g....g....
B35091.SEQ   (   499) ......................................g......g....
B35092.SEQ   (   426) ......................................g......g....
B3510.SEQ    (   426) ......................................g......g....
B3511.SEQ    (   426) ......................................g......g....
B3512.SEQ    (   426) ......................................g......g....
B3513.SEQ    (   426) ......................................g......g....
B3514.SEQ    (   426) ............................a.........gtg....g....
B3516.SEQ    (   499) ......................................g......g....
B3517.SEQ    (   426) ......................................g......g....
B3518.SEQ    (   426) ......................................g.g....g....
B3519.SEQ    (   426) ......................................g......g....
B3520.SEQ    (   426) ......................................g......g....
B3521.SEQ    (   426) ............................a.........g......g....
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B3522.SEQ    (   426) ......................................g......g....
B3523.SEQ    (   426) ......................................g......g....
B3524.SEQ    (   426) ......................................g......g....
B3525.SEQ    (   426) ......................................g......g....
NM3          (   418) cctggagggcctgtgcgtggagtggctccgcagatacctgganaacggga
B3501.SEQ    (   549) ..........................................g.......
B3502.SEQ    (   549) ..........................................g.......
B3503.SEQ    (   550) ..........................................g.......
B3504.SEQ    (   549) ..........................................g.......
B3505.SEQ    (   549) ..........................................g.......
B3506.SEQ    (   549) ..........................................g.......
B3507.SEQ    (   549) ..........................................g.......
B3508.SEQ    (   549) ..........................................g.......
B35091.SEQ   (   549) ..........................................g.......
B35092.SEQ   (   476) ..........................................g.......
B3510.SEQ    (   476) ..........................................g.......
B3511.SEQ    (   476) ..........................................g.......
B3512.SEQ    (   476) ..........................................g.......
B3513.SEQ    (   476) ..........................................g.......
B3514.SEQ    (   476) ..........................................g.......
B3516.SEQ    (   549) ..........ga..............................g.......
B3517.SEQ    (   476) ..........................................g.......
B3518.SEQ    (   476) ..........................................g.......
B3519.SEQ    (   476) ..........................................g.......
B3520.SEQ    (   476) ..........................................g.......
B3521.SEQ    (   476) ..................................c.......g.......
B3522.SEQ    (   476) ..........................................g.......
B3523.SEQ    (   476) ..........................................g.......
B3524.SEQ    (   476) ..................................c.......g.......
B3525.SEQ    (   476) ..................................c.......g.......
NM3          (   468) aggagacgctgcancgcgcggaccccccaaagacacacgtgacccaccac
B3501.SEQ    (   599) .............g....................................
B3502.SEQ    (   599) .............g....................................
B3503.SEQ    (   600) .............g....................................
B3504.SEQ    (   599) .............g....................................
B3505.SEQ    (   599) .............g....................................
B3506.SEQ    (   599) .............g....................................
B3507.SEQ    (   599) .............g....................................
B3508.SEQ    (   599) .............g....................................
B35091.SEQ   (   599) .............g....................................
B35092.SEQ   (   526) .............g.......-----------------------------
B3510.SEQ    (   526) --------------------------------------------------
B3511.SEQ    (   526) --------------------------------------------------
B3512.SEQ    (   526) --------------------------------------------------
B3513.SEQ    (   526) .............g.......-----------------------------
B3514.SEQ    (   526) .............g.......-----------------------------
B3516.SEQ    (   599) .............g....................................
B3517.SEQ    (   526) .............g.......-----------------------------
B3518.SEQ    (   526) .............g.......-----------------------------
B3519.SEQ    (   526) .............g.......-----------------------------
B3520.SEQ    (   526) .............g.......-----------------------------
B3521.SEQ    (   526) .............g.......-----------------------------
B3522.SEQ    (   526) .............g.......-----------------------------
B3523.SEQ    (   526) .............g.......-----------------------------
B3524.SEQ    (   526) .............g.......-----------------------------
B3525.SEQ    (   526) .............g.......-----------------------------
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NM3          (   518) cccgtctctgaccatgaggccaccctgaggtgctgggccctgggcttcta
B3501.SEQ    (   649) ..................................................
B3502.SEQ    (   649) ..................................................
B3503.SEQ    (   650) ..................................................
B3504.SEQ    (   649) ..................................................
B3505.SEQ    (   649) ..................................................
B3506.SEQ    (   649) ..................................................
B3507.SEQ    (   649) ..................................................
B3508.SEQ    (   649) ..................................................
B35091.SEQ   (   649) ..................................................
B35092.SEQ   (   547) --------------------------------------------------
B3510.SEQ    (   526) --------------------------------------------------
B3511.SEQ    (   526) --------------------------------------------------
B3512.SEQ    (   526) --------------------------------------------------
B3513.SEQ    (   547) --------------------------------------------------
B3514.SEQ    (   547) --------------------------------------------------
B3516.SEQ    (   649) ..................................................
B3517.SEQ    (   547) --------------------------------------------------
B3518.SEQ    (   547) --------------------------------------------------
B3519.SEQ    (   547) --------------------------------------------------
B3520.SEQ    (   547) --------------------------------------------------
B3521.SEQ    (   547) --------------------------------------------------
B3522.SEQ    (   547) --------------------------------------------------
B3523.SEQ    (   547) --------------------------------------------------
B3524.SEQ    (   547) --------------------------------------------------
B3525.SEQ    (   547) --------------------------------------------------
NM3          (   568) ccctgcggagatcacnctgacctggcancgggatggcgaggaccaaactc
B3501.SEQ    (   699) ...............a...........g......................
B3502.SEQ    (   699) ...............a...........g......................
B3503.SEQ    (   700) ...............a...........g......................
B3504.SEQ    (   699) ...............a...........g......................
B3505.SEQ    (   699) ...............a...........g......................
B3506.SEQ    (   699) ...............a...........g......................
B3507.SEQ    (   699) ...............a...........g......................
B3508.SEQ    (   699) ...............a...........g......................
B35091.SEQ   (   699) ...............a...........g......................
B35092.SEQ   (   547) --------------------------------------------------
B3510.SEQ    (   526) --------------------------------------------------
B3511.SEQ    (   526) --------------------------------------------------
B3512.SEQ    (   526) --------------------------------------------------
B3513.SEQ    (   547) --------------------------------------------------
B3514.SEQ    (   547) --------------------------------------------------
B3516.SEQ    (   699) ...............a...........g......................
B3517.SEQ    (   547) --------------------------------------------------
B3518.SEQ    (   547) --------------------------------------------------
B3519.SEQ    (   547) --------------------------------------------------
B3520.SEQ    (   547) --------------------------------------------------
B3521.SEQ    (   547) --------------------------------------------------
B3522.SEQ    (   547) --------------------------------------------------
B3523.SEQ    (   547) --------------------------------------------------
B3524.SEQ    (   547) --------------------------------------------------
B3525.SEQ    (   547) --------------------------------------------------
NM3          (   618) aggacactgancttgtggagacc---------------------------
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B3501.SEQ    (   749) ..........g............agaccagcaggagatagaaccttccag
B3502.SEQ    (   749) ..........g............agaccagcaggagatagaaccttccag
B3503.SEQ    (   750) ..........g............agaccagcaggagatagaaccttccag
B3504.SEQ    (   749) ..........g............agaccagcaggagatagaaccttccag
B3505.SEQ    (   749) ..........g............agaccagcaggagatagaaccttccag
B3506.SEQ    (   749) ..........g............agaccagcaggagatagaaccttccag
B3507.SEQ    (   749) ..........g............agaccagcaggagatagaaccttccag
B3508.SEQ    (   749) ..........g............agaccagcaggagatagaaccttccag
B35091.SEQ   (   749) ..........g............agaccagcaggagatagaaccttccag
B35092.SEQ   (   547) ----------------------.---------------------------
B3510.SEQ    (   526) ----------------------.---------------------------
B3511.SEQ    (   526) ----------------------.---------------------------
B3512.SEQ    (   526) ----------------------.---------------------------
B3513.SEQ    (   547) --------------------------------------------------
B3514.SEQ    (   547) --------------------------------------------------
B3516.SEQ    (   749) ..........g............agaccagcaggagatagaaccttccag
B3517.SEQ    (   547) --------------------------------------------------
B3518.SEQ    (   547) --------------------------------------------------
B3519.SEQ    (   547) --------------------------------------------------
B3520.SEQ    (   547) --------------------------------------------------
B3521.SEQ    (   547) --------------------------------------------------
B3522.SEQ    (   547) --------------------------------------------------
B3523.SEQ    (   547) --------------------------------------------------
B3524.SEQ    (   547) --------------------------------------------------
B3525.SEQ    (   547) --------------------------------------------------
